Evidence map›Paper›PMID 34052957›Full record

ArticleInternational urology and nephrology2021

Head-to-head comparison of prostatic urethral lift and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: a real-life study.

Michael Baboudjian, Marc Fourmarier, Bastien Gondran-Tellier, Benjamin Pradere, Mickael Userovici, Camille Alegorides, Nicolas Barry Delongchamps

Abstract readComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Michael BaboudjianDepartment of Urology, Aix-en-Provence Hospital, Aix en Provence, France. Michael.BABOUDJIAN@ap-hm.fr.ORCID http://orcid.org/0000-0001-6935-3873
Marc FourmarierDepartment of Urology, Aix-en-Provence Hospital, Aix en Provence, France.
Bastien Gondran-TellierDepartment of Urology and Kidney Transplantation, La Conception Hospital, AixMarseille University, APHM, Marseille, France.
Benjamin PradereDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Mickael UseroviciDepartment of Urology, Cochin Hospital, APHP, University of Paris Descartes, Paris, France.
Camille AlegoridesDepartment of Urology, Aix-en-Provence Hospital, Aix en Provence, France.
Nicolas Barry DelongchampsDepartment of Urology, Cochin Hospital, APHP, University of Paris Descartes, Paris, France.
Centre Hospitalier du Pays d'Aix · FRDélégation Paris 5 · FRAix-Marseille Université · FRComprehensive Cancer Center Vienna · ATHôpital de la Conception · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed at reporting a head-to-head comparison between water vapor thermal therapy using the Rezūm™ system and prostatic urethral lift using the Urolift™ system in men with lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). PATIENTS AND

methodsFrom December 2017 to November 2019, consecutive patients who underwent Rezūm™ and Urolift™ procedures in two urology centers have been retrospectively considered. Only patients with a prostate size less than 80 mL were included. We used the PSM method to adjust baseline differences between both groups. The co-primary endpoint included the change in International Prostate Symptom Score (IPSS) and IPSS- quality of life (QoL) from baseline to 12 months.

resultsA total of 61 (52.1%) and 56 (47.9%) patients underwent Rezum™ and Urolift™ procedures, respectively. After PSM adjustment, 24 patients were included in both groups. No serious adverse events occurred (> Clavien II) in both groups. At 12 months, higher IPSS improvement was observed in the Rezum™ group (median:4 [IQR 3-5]) than in the Urolift™ group (median:8 [IQR 7-12]), without statistical difference (p = 0.08). The improvement in term of QoL at 12 m was similar (p = 0.43). The retreatment rates were 25% (Urolift™) and 8.3% (Rezum™), p = 0.24. Erection and ejaculatory function scores did not change significantly in either treatment group. Results in the full cohort showed that Rezum™ appeared to deliver greater improvements for IPSS and IPSS-QoL (p < 0.001 and p = 0.006, respectively) and lower reintervention rate (p = 0.006) than Urolift™.

conclusionsIn this small retrospective study, our results indicate that both Rezum™ and Urolift™ provide a clinically significant improvement in symptoms and QoL, although some of these improvements were greater in the Rezum™ arm. Future studies are needed to definitively assess which treatment would be best suited for each patient.

Indexed as

SteamAblation TechniquesAgedHumansHyperthermia, InducedLower Urinary Tract SymptomsMaleMiddle AgedProstatic HyperplasiaQuality of LifeRetrospective StudiesTreatment OutcomeUrethraUrologic Surgical ProceduresSteamBenign prostatic hyperplasiaLower urinary tract symptomsMinimally invasive surgical treatmentProstatic urethral liftWater vapor thermal therapy

Identifiers

PMID34052957
OpenAlexW3164443449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.